|
1
|
Zhou J, Li J, Wang Z, Yin C and Zhang W:
Metadherin is a novel prognostic marker for bladder cancer
progression and overall patient survival. Asia Pac J Clin Oncol.
8:e42–e48. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Jemal A, Siegel R, Xu J and Ward E: Cancer
statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Huang P, Chen J, Wang L, Na Y, Kaku H,
Ueki H, Sasaki K, Yamaguchi K, Zhang K, Saika T, et al:
Implications of transcriptional factor, OCT-4, in human bladder
malignancy and tumor recurrence. Med Oncol. 29:829–834. 2012.
View Article : Google Scholar
|
|
4
|
Denzinger S, Mohren K, Knuechel R, Wild
PJ, Burger M, Wieland WF, Hartmann A and Stoehr R: Improved
clonality analysis of multifocal bladder tumors by combination of
histopathologic organ mapping, loss of heterozygosity, fluorescence
in situ hybridization, and p53 analyses. Hum Pathol. 37:143–151.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Marr BP, Hung C, Gobin YP, Dunkel IJ,
Brodie SE and Abramson DH: Success of intra-arterial chemotherapy
(chemosurgery) for retinoblastoma: Effect of orbitovascular
anatomy. Arch Ophthalmol. 130:180–185. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ghassemi F and Shields CL: Intravitreal
melphalan for refractory or recurrent vitreous seeding from
retinoblastoma. Arch Ophthalmol. 130:1268–1271. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Munier FL, Gaillard M-C, Balmer A, Soliman
S, Podilsky G, Moulin AP and Beck-Popovic M: Intravitreal
chemotherapy for vitreous disease in retinoblastoma revisited: From
prohibition to conditional indications. Br J Ophthalmol.
96:1078–1083. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhuang Y and Miskimins WK: Cell cycle
arrest in metformin treated breast cancer cells involves activation
of AMPK, downregulation of cyclin D1, and requires
p27Kip1 or p21Cip1. J Mol Signal. 3:182008.
View Article : Google Scholar
|
|
9
|
Liu B, Fan Z, Edgerton SM, Deng XS,
Alimova IN, Lind SE and Thor AD: Metformin induces unique
biological and molecular responses in triple negative breast cancer
cells. Cell Cycle. 8:2031–2040. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Cooper CS, Nicholson AG, Foster C, Dodson
A, Edwards S, Fletcher A, Roe T, Clark J, Joshi A, Norman A, et al:
Nuclear overexpression of the E2F3 transcription factor in human
lung cancer. Lung Cancer. 54:155–162. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Chen YC, Xu L, Guo YL, Su HJ, Smith TJ,
Ryan LM, Lee MS and Christiani DC: Polymorphisms in GSTT1 and p53
and urinary transitional cell carcinoma in south-western Taiwan: A
preliminary study. Biomarkers. 9:386–394. 2004. View Article : Google Scholar
|
|
12
|
Lin HY, Huang CH, Wu WJ, Chou YH, Fan PL
and Lung FW: Mutation of the p53 tumor suppressor gene in
transitional cell carcinoma of the urinary tract in Taiwan.
Kaohsiung J Med Sci. 21:57–64. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wu X, Cai ZD, Lou LM and Zhu YB:
Expressions of p53, c-MYC, BCL-2 and apoptotic index in human
osteosarcoma and their correlations with prognosis of patients.
Cancer Epidemiol. 36:212–216. 2012. View Article : Google Scholar
|
|
14
|
Mojtahedi Z, Hashemi SB, Khademi B, Karimi
M, Haghshenas MR, Fattahi MJ and Ghaderi A: p53 codon 72
polymorphism association with head and neck squamous cell
carcinoma. Braz J Otorhinolaryngol. 76:316–320. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Sartor M, Steingrimsdottir H, Elamin F,
Gäken J, Warnakulasuriya S, Partridge M, Thakker N, Johnson NW and
Tavassoli M: Role of p16/MTS1, cyclin D1 and RB in primary oral
cancer and oral cancer cell lines. Br J Cancer. 80:79–86. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Tanaka N, Ogi K, Odajima T, Dehari H,
Yamada S, Sonoda T and Kohama G: pRb2/p130 protein expression is
correlated with clinicopathologic findings in patients with oral
squamous cell carcinoma. Cancer. 92:2117–2125. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhou HX, Li XY, Li FY, Liu C, Liang ZP,
Liu S, Zhang B, Wang TY, Chu TC, Lu L, et al: Targeting RPTPσ with
lentiviral shRNA promotes neurites outgrowth of cortical neurons
and improves functional recovery in a rat spinal cord contusion
model. Brain Res. 1586:46–63. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Shields CL, Shelil A, Cater J, Meadows AT
and Shields JA: Development of new retinoblastomas after 6 cycles
of chemo-reduction for retinoblastoma in 162 eyes of 106
consecutive patients. Arch Ophthalmol. 121:1571–1576. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ferrari S, Bertoni F, Zanella L, Setola E,
Bacchini P, Alberghini M, Versari M and Bacci G: Evaluation of
P-glycoprotein, HER-2/ErbB-2, p53, and Bcl-2 in primary tumor and
metachronous lung metastases in patients with high-grade
osteosarcoma. Cancer. 100:1936–1942. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Sarbassov DD, Ali SM and Sabatini DM:
Growing roles for the mTOR pathway. Curr Opin Cell Biol.
17:596–603. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Foster CS, Falconer A, Dodson AR, Norman
AR, Dennis N, Fletcher A, Southgate C, Dowe A, Dearnaley D, Jhavar
S, et al: Transcription factor E2F3 overexpressed in prostate
cancer independently predicts clinical outcome. Oncogene.
23:5871–5879. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ziebold U, Reza T, Caron A and Lees JA:
E2F3 contributes both to the inappropriate proliferation and to the
apoptosis arising in Rb mutant embryos. Genes Dev. 15:386–391.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
McClellan KA, Ruzhynsky VA, Douda DN,
Vanderluit JL, Ferguson KL, Chen D, Bremner R, Park DS, Leone G and
Slack RS: Unique requirement for Rb/E2F3 in neuronal migration:
Evidence for cell cycle-independent functions. Mol Cell Biol.
27:4825–4843. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Oeggerli M, Tomovska S, Schraml P,
Calvano-Forte D, Schafroth S, Simon R, Gasser T, Mihatsch MJ and
Sauter G: E2F3 amplification and overexpression is associated with
invasive tumor growth and rapid tumor cell proliferation in urinary
bladder cancer. Oncogene. 23:5616–5623. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Bärlund M, Forozan F, Kononen J, Bubendorf
L, Chen Y, Bittner ML, Torhorst J, Haas P, Bucher C, Sauter G, et
al: Detecting activation of ribosomal protein S6 kinase by
complementary DNA and tissue microarray analysis. J Natl Cancer
Inst. 92:1252–1259. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Urquidi V, Kim J, Chang M, Dai Y, Rosser
CJ and Goodison S: CCL18 in a multiplex urine-based assay for the
detection of bladder cancer. PLoS One. 7:e377972012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Eruslanov E, Neuberger M, Daurkin I,
Perrin GQ, Algood C, Dahm P, Rosser C, Vieweg J, Gilbert SM and
Kusmartsev S: Circulating and tumor-infiltrating myeloid cell
subsets in patients with bladder cancer. Int J Cancer.
130:1109–1119. 2012. View Article : Google Scholar
|
|
29
|
Mitra AP, Hansel DE and Cote RJ:
Prognostic value of cell-cycle regulation biomarkers in bladder
cancer. Semin Oncol. 39:524–533. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kato K, Gong J, Iwama H, Kitanaka A, Tani
J, Miyoshi H, Nomura K, Mimura S, Kobayashi M, Aritomo Y, et al:
The antidiabetic drug metformin inhibits gastric cancer cell
proliferation in vitro and in vivo. Mol Cancer Ther. 11:549–560.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Schefler AC, Cicciarelli N, Feuer W,
Toledano S and Murray TG: Macular retinoblastoma: Evaluation of
tumor control, local complications, and visual outcomes for eyes
treated with chemotherapy and repetitive foveal laser ablation.
Ophthalmology. 114:162–169. 2007. View Article : Google Scholar
|
|
32
|
Shields CL: Forget-me-nots in the care of
children with retinoblastoma. Semin Ophthalmol. 23:324–334. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Shields CL, Palamar M, Sharma P,
Ramasubramanian A, Leahey A, Meadows AT and Shields JA:
Retinoblastoma regression patterns following chemoreduction and
adjuvant therapy in 557 tumors. Arch Ophthalmol. 127:282–290. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Yang L, Meng Y, Bao C, Liu W, Ma C, Li A,
Xuan Z, Shan G and Jia Y: Robustness and backbone motif of a cancer
network regulated by miR-17-92 cluster during the G1/S
transition. PLoS One. 8:e570092013. View Article : Google Scholar
|
|
35
|
Humbert PO, Verona R, Trimarchi JM, Rogers
C, Dandapani S and Lees JA: E2f3 is critical for normal cellular
proliferation. Genes Dev. 14:690–703. 2000.PubMed/NCBI
|
|
36
|
Buzzai M, Jones RG, Amaravadi RK, Lum JJ,
DeBerardinis RJ, Zhao F, Viollet B and Thompson CB: Systemic
treatment with the antidiabetic drug metformin selectively impairs
p53-deficient tumor cell growth. Cancer Res. 67:6745–6752. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Callagy GM, Pharoah PD, Pinder SE, Hsu FD,
Nielsen TO, Ragaz J, Ellis IO, Huntsman D and Caldas C: Bcl-2 is a
prognostic marker in breast cancer independently of the Nottingham
Prognostic Index. Clin Cancer Res. 12:2468–2475. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Dawson SJ, Makretsov N, Blows FM, Driver
KE, Provenzano E, Le Quesne J, Baglietto L, Severi G, Giles GG,
McLean CA, et al: BCL2 in breast cancer: A favourable prognostic
marker across molecular subtypes and independent of adjuvant
therapy received. Br J Cancer. 103:668–675. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Tse C, Shoemaker AR, Adickes J, Anderson
MG, Chen J, Jin S, Johnson EF, Marsh KC, Mitten MJ, Nimmer P, et
al: ABT-263: A potent and orally bioavailable Bcl-2 family
inhibitor. Cancer Res. 68:3421–3428. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Nedelcu T, Kubista B, Koller A, Sulzbacher
I, Mosberger I, Arrich F, Trieb K, Kotz R and Toma CD: Livin and
Bcl-2 expression in high-grade osteosarcoma. J Cancer Res Clin
Oncol. 134:237–244. 2008. View Article : Google Scholar
|
|
41
|
Wang ZX, Yang JS, Pan X, Wang JR, Li J,
Yin YM and De W: Functional and biological analysis of Bcl-xL
expression in human osteosarcoma. Bone. 47:445–454. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Wensveen FM, Alves NL, Derks IA, Reedquist
KA and Eldering E: Apoptosis induced by overall metabolic stress
converges on the Bcl-2 family proteins Noxa and Mcl-1. Apoptosis.
16:708–721. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Petroulakis E, Mamane Y, Le Bacquer O,
Shahbazian D and Sonenberg N: mTOR signaling: Implications for
cancer and anticancer therapy. Br J Cancer. 94:195–199. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Murayama T, Inokuchi M, Takagi Y, Yamada
H, Kojima K, Kumagai J, Kawano T and Sugihara K: Relation between
outcomes and localisation of p-mTOR expression in gastric cancer.
Br J Cancer. 100:782–788. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Fajas L, Landsberg RL, Huss-Garcia Y,
Sardet C, Lees JA and Auwerx J: E2Fs regulate adipocyte
differentiation. Dev Cell. 3:39–49. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Liu J, Li M, Song B, Jia C, Zhang L, Bai X
and Hu W: Metformin inhibits renal cell carcinoma in vitro and in
vivo xenograft. Urol Oncol. 31:264–270. 2013. View Article : Google Scholar
|
|
47
|
Shaw RJ, Lamia KA, Vasquez D, Koo SH,
Bardeesy N, Depinho RA, Montminy M and Cantley LC: The kinase LKB1
mediates glucose homeostasis in liver and therapeutic effects of
metformin. Science. 310:1642–1646. 2005. View Article : Google Scholar : PubMed/NCBI
|
